Eli Lilly agreed to acquire Houston-based ADC specialist CrossBridge Bio for up to $300M (undisclosed upfront + development milestone). Lead asset CBB-120 is a preclinical TROP2-targeting dual-payload (TOP1i + ATRi) ADC positioned to differentiate from existing TROP2 ADCs. Extends Lilly's precision oncology build-out post Loxo.